Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease by Mustapić, Maja et al.
  
    
 
Središnja medicinska knjižnica 
 
 
 
 
Mustapić M., Presečki P., Pivac N., Mimica N., Hof P. R., Šimić G., 
Folnegović-Šmalc V., Muck-Šeler D. (2013) Genotype-independent 
decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's 
disease. Progress in Neuro-Psychopharmacology & Biological 
Psychiatry, 44 (1). pp. 94-9. ISSN 0278-5846 
 
 
http://www.elsevier.com/locate/issn/02785846 
 
http://www.sciencedirect.com/science/journal/02785846 
 
http://dx.doi.org/10.1016/j.pnpbp.2013.02.002 
 
 
 
http://medlib.mef.hr/2048 
 
 
University of Zagreb Medical School Repository 
http://medlib.mef.hr/ 
   
 
 
 
 
 
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer’s 
disease  
Maja Mustapic
a
, Paola Presecki
b
, Nela Pivac
a
, Ninoslav Mimica
c
, Patrick R. Hof
d
, Goran 
Simic
e
, Vera Folnegovic-Smalc
c
, Dorotea Muck-Seler
a* 
a 
Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, HR-10000 Zagreb, 
Croatia 
b
Psychiatric Hospital Sveti Ivan, Jankomir 11, pp 68, HR-10090 Zagreb, Croatia  
c 
University Psychiatric Hospital Vrapce, Bolnicka cesta 32, HR-10090 Zagreb, Croatia 
d
 Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of 
Medicine at Mount Sinai, New York, NY 10029, USA 
e 
Department of Neuroscience, Croatian Institute for Brain Research, Medical School   
University of Zagreb, Salata 12, HR-10000 Zagreb, Croatia 
Corresponding author: 
*Dorotea Muck-Seler, PhD, senior scientist  
Laboratory of Molecular Neuropsychiatry, Division of Molecular Medicine   
Rudjer Boskovic Institute, Bijenicka 54, HR-10000 Zagreb, Croatia 
Tel: 385-1- 4571 207; Fax- 385-1- 4561 010; E-mail: seler@irb.hr 
 2
Abstract  
The noradrenergic system is involved in the etiology and progression of Alzheimer’s disease 
(AD) but its role is still unclear. Dopamine beta-hydroxylase (DBH) as a catecholamine-
synthesizing enzyme plays a central role in noradrenaline (NA) synthesis and turnover. Plasma 
DBH (pDBH) activity shows wide inheritable interindividual variability that is under genetic 
control. The aim of this study was to determine pDBH activity, DBH (C-970T; rs1611115) and 
DBH (C1603T; rs6271) gene polymorphisms in 207 patients with AD and in 90 healthy age-
matched controls. Plasma DBH activity was lower, particularly in the early stage of AD, 
compared to values in middle and late stages of the disease, as well as to control values. Two-
way ANOVA revealed significant effect of both diagnosis and DBH (C-970T) or DBH 
(C1603T) genotypes on pDBH activity, but without significant diagnosis x genotype 
interaction. No association was found between AD and DBH C-970T (OR = 1.08, 95% CI 
1.13-4.37; p = 0.779) and C1603T (OR = 0.89; 95% CI 0.36-2.20; p = 0.814) genotypes 
controlled for age, gender, and ApoE4 allele. The decrease in pDBH activity, found in early 
phase of AD suggests that alterations in DBH activity represent a compensatory mechanism for 
the loss of noradrenergic neurons, and that treatment with selective NA reuptake inhibitors may 
be indicated in early stages of AD to compensate for loss of noradrenergic activity in the locus 
coeruleus. 
 
Keywords:  
Alzheimer’s disease; Cognitive decline; Dopamine beta-hydroxylase; DBH gene 
polymorphisms; Plasma DBH activity   
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Abbreviations: Aβ, amyloid β protein; AD, Alzheimer’s disease; ANOVA, one-way analysis 
of variance; CSF, cerebrospinal fluid; DBH, dopamine beta-hydroxylase; DBH, dopamine beta-
hydroxylase gene; LC, locus coeruleus; MHPG, 3-methoxy-4-hydroxyphenylglycol; MMSE, 
Mini-Mental State Examination; NA, noradrenaline; pDBH, plasma dopamine beta-
hydroxylase;  
 
1. Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by 
memory loss and cognitive impairment. Because aging is one of the main risk factors for AD 
and due to the generalized increase in life expectancy, the prevalence of AD among individuals 
above 65 years of age is rapidly increasing and AD represents a major public health problem 
worldwide (Alzheimer's Association, 2010).    
None of the many hypotheses of the etiology of AD has successfully explained all of 
the features of the disease. AD is a multifactorial disease with a complex interplay of many 
genetic and environmental factors resulting in a network of interactions that still have to be 
deciphered. Neuroimaging studies have revealed brain atrophy in the neocortex, hippocampus, 
and several other brain regions (Cummings, 2004). Dysfunction in cholinergic system was 
recognized early (Coyle et al. , 1983, Giacobini, 2003; Lyness et al., 2003; Wenk, 2003). The 
loss of serotonergic and noradrenergic nuclei in the brainstem has also been reported in patients 
with AD (Herrmann et al., 2004; Garcia-Alloza et al., 2005) implying a role for these 
neurotransmitter systems in the etiology of AD (Lyness et al., 2003).   
The noradrenergic system has two main projections, one originating from noradrenergic 
cells bodies in the ventrolateral tegmental area that is involved in sexual and feeding behaviors, 
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and the other, originating from the locus coeruleus (LC), associated with learning, memory and 
cognitive functions (Grudzien et al., 2007; Heneka et al., 2010). The loss of noradrenergic 
neurons from LC correlates with the increase of extracellular amyloid β protein (Aβ) 
deposition in mice (Heneka et al., 2010), neurofibrillary abnormalities in early stage of AD 
(Grudzien et al., 2007), onset (American Psychiatric Association., 1994, Counts and Mufson, 
2010), and duration of dementia (Forstl et al., 1994; Counts and Mufson, 2010). In AD, reduced 
concentration of noradrenaline (NA) has been reported in many brain regions (Herrmann et al., 
2004; Hoogendijk et al., 1999). In addition, increases in cerebrospinal fluid (CSF) NA levels 
(Elrod et al., 1997; Raskind et al., 1999) in AD support the hypothesis that increased 
noradrenergic activity represents a compensatory mechanism for both cholinergic and 
noradrenergic deficits (Giubilei et al. , 2004; Herrmann et al., 2004). There are several 
mechanisms providing evidence for the role of NA in AD as not merely a risk factor but as an 
actual etiological factor (Counts and Mufson, 2010; Fitzgerald, 2010; Weinshenker, 2008). 
Neuronal plasticity resulting in hyperinnervation of the forebrain regions and noradrenergic 
sprouting to reinnervate brain regions marked by loss of cholinergic neurons might be 
mechanisms that account for this compensation (Szot et al., 2006; McMillan et al., 2011). Apart 
from its role as a neurotransmitter, NA may act as an endogenous anti-inflammatory agent by 
inhibition of inflammatory activation of microglial cells (Feinstein et al., 2002; Heneka and 
O'Banion, 2007). Therefore, it has been suggested that cell death in LC and the loss of NA-
mediated anti-inflammatory protection could exacerbate inflammation and contribute to the 
pathogenesis of AD.  
The enzyme dopamine beta-hydroxylase (DBH) catalyzes the oxidative hydroxylation 
of dopamine to NA. DBH is present in noradrenergic neurons in the central nervous system, 
peripheral postganglionic sympathetic neurons, and adrenal medulla (Kim et al., 2002). It is the 
only catecholamine-synthesizing enzyme within synaptic vesicles, where it exists in soluble 
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and membrane-bound forms (Lewis and Asnani, 1992). DBH is co-released by exocytosis 
together with NA and can be found in CSF, plasma, and serum (Weinshilboum et al., 1971). 
The enzymatic activity of pDBH is characterized by wide interindividual variation regulated by 
genetic inheritance (Cubells and Zabetian, 2004). The enzymatic activity of DBH corresponds 
to the plasma level of DBH protein (Weinshilboum et al., 1973; O'Connor et al., 1994) is quite 
stable, and does not change after physical activity (Cubells and Zabetian, 2004). Single 
nucleotide polymorphism in the promoter region C-970T of the DBH gene (rs1611115, 
formerly called C-1021T) accounts for 30 to 50% of the variance in DBH activity, and the T-
970 allele contributes to decreased pDBH activity through co-dominant inheritance (Zabetian 
et al., 2003). The next plausible variant at DBH locus accounting for the variance in pDBH 
activity, but with considerably less effect is the C1603T polymorphism in intron 11 (Zabetian 
et al., 2003; Tang et al., 2005).  
Although DBH modulates NA levels (Burke et al., 1999; McMillan et al., 2011; Szot et 
al., 2006) little is known about the effect of DBH activity and/or NA turnover on the 
development and progression of AD. In patients with AD, reduced DBH activity was found in 
hippocampus and neocortex postmortem (Cross et al., 1981, Perry et al., 1981). It is possible 
that the -970T allele and consequently lowered DBH activity in patients with AD could be 
responsible for the reduced synthesis of NA and loss of its neuroprotective role (Heneka et al.,  
2010; Mateo et al., 2006; Weinshenker, 2008; Wenk et al., 2003). 
Our hypothesis was that pDBH activity could be a biomarker for the development and 
cognitive dysfunction in AD. Because pDBH activity is genotype-controlled, the aim of the 
present study was to determine pDBH activity and C-970T and C1603T DBH gene 
polymorphisms in patients with AD and healthy age-matched control subjects. As so far no 
study has analyzed the relationship between pDBH activity and cognitive function in patients 
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with AD, we measured pDBH activity in early, middle, and late phases of AD, to elucidate the 
possible involvement of DBH,, and consequently of NA in the progress of AD. 
 
2. Methods 
2.1. Study population 
The present study included 297 unrelated Croatian Caucasian subjects: 207 patients 
with probable sporadic late onset AD (mean age 80 ± 7.1; range 65-98 years; 185 women), who 
were recruited from the Psychiatric Clinic Vrapce, Zagreb, Croatia, and a control group of 90 
healthy, elderly volunteers (mean age 77.0 ± 7.9; range 60-90 years; 67 women) from local 
elder living communities. The diagnosis of probable AD was made according to the DSM-IV 
(American Psychiatric Association., 1994) and the criteria of the National Institute of 
Neurologic and Communicative Disorders and Stroke and the Alzheimer‘s Disease and Related 
Disorders Association (NINDS-ADRDA) (McKhann et al., 1984). All subjects underwent a 
clinical interview to rule out for Axis I disorders and to evaluate current and past medical 
status. Exclusion criteria for patients and controls were the diagnoses of severe somatic 
diseases (heart disease, epilepsy, brain trauma, cancer), major functional psychiatric disorders 
(depression, schizophrenia), hypertension, smoking, and alcoholism. Patients were treated with 
acetylcholinesterase inhibitors, and some received antipsychotics, but were medication-free for 
at least one week before blood sampling. Their cognitive status was evaluated with the Mini-
Mental State Examination (MMSE) (Folstein et al., 1975) that was translated and validated to 
the Croatian population (www.parinc.com; Boban et al., 2012). MMSE scores (expressed as 
mean ± standard deviations) were 28.56 ± 1.94 (range 26-30) and 11.69 ± 8.14 (range 0-24) in 
controls and in patients with AD, respectively. Patients were additionally subdivided according 
to the MMSE scores into three groups: 47 patients in the early (20.67 ± 1.3; range 19-24), 80 
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patients in the middle (14.27 ± 2.1; range 10-18) and 80 patients in the late (1.58 ± 2.4; range 
0-9) phases of AD. The study was approved by the local Ethics Committee of the University 
Psychiatric Hospital Vrapce. All of the patients or their proxies and the healthy controls gave 
informed consent. The study was performed in accordance with the ethical standards laid down 
in the 1964 Declaration of Helsinki.  
 
2.2. Biochemical and molecular analyses 
Blood samples (4 ml) were taken in a plastic syringe with 1 ml of acid citrate dextrose as an 
anticoagulant. Plasma was obtained after centrifugation of blood at 5,000 x g for 10 min, and 
stored at -20°C until assayed using modified method of Nagatsu and Udenfriend  (Nagatsu and 
Udenfriend, 1972). Briefly, DBH converts substrate tyramine to octopamine, which is oxidized 
to p-hydroxybenzaldehyde, and measured photometrically at 330 nm. The full protocol is 
available at http://hypertension.ucsd.edu/list_of_protocols/25_DBH_assay.htm.  
Genomic DNA was extracted from blood samples using standard salting out procedure 
(Miller et al., 1988). Genotyping of DBH (C-970T; rs1611115), DBH (C1603T; rs6271), and 
ApoE (rs7412, rs429358) polymorphisms were performed in ABI Prism 7000 Sequencing 
Detection System apparatus (ABI, Foster City, CA  USA) using a TaqMan-based allele-
specific polymerase chain reaction assays, according to the procedure described by Applied 
Biosystems (ABI, Foster City, CA, USA). The primers and probes were purchased from ABI 
Assay ID numbers are available upon request. 
 
2.3. Statistical analysis 
The results were expressed as means ± standard deviations. Differences in pDBH activity 
among groups were evaluated with one-way analysis of variance (ANOVA) and Tukey’s test. 
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Because the data for pDBH activity were not normally distributed, they were natural logarithm-
transformed. Two-way ANOVA was used to test the effect and interaction of diagnosis (AD 
and healthy controls) and genotype (CC, CT, TT) on plasma DBH activity. The correlation 
between age and pDBH activity was determined by a Spearman’s coefficient of correlation. 
The deviations from Hardy-Weinberg equilibrium, and genotype and allele distributions were 
performed by the χ
2
 test. Logistic regression was applied to test the association of AD and 
DBH (C-970T) and DBH (C1603T) genotypes TT+CT vs. CC, controlled for age, gender, and 
ApoE4 allele. Power was set to 0.8. The determination of the minimum sample size required to 
achieve a desired power were evaluated using Sigma Stat 3.5. The statistical packages used 
were GraphPad Prism and Sigma Stat 3.5 (Jandell Scientific Corp. San Raphael, California, 
USA). The level of significance was set to α = 0.05, with 2-tailed p values.  
 
 
3. Results  
 
3.1. Plasma DBH activity 
One-way ANOVA revealed that pDBH activity did not differ (F = 2.103; df = 1,88; p = 
0.151) between healthy women (15.26 ± 10.9 nmol/ml/min) and men (18.39 ± 10.8 
nmol/ml/min) or between women (9.07 ± 5.9 nmol/ml/min) and men (8.21 ± 6.1 nmol/ml/min) 
with AD (F = 1.093; df = 1,205; p = 0.297). Therefore, in further analyses the results from both 
genders were collapsed. Significantly lower pDBH activity was detected in patients with AD 
(8.98 ± 5.87 nmol/ml/min) compared to values of pDBH activity in healthy control subjects 
(16.09 ± 10.9 nmol/ml/min) (F = 39.2; df = 1,295; p <0.001; power = 1.00 with sufficient 
sample size). No significant correlation (Spearman’s coefficient of correlation) was found 
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between pDBH activity and age in 90 healthy control subjects (r = -0.079; p = 0.175) or in 207 
patients with AD (r = -0.093; p =0.141).  
Plasma DBH activity was significantly different (F = 10.251; df= 3, 294; p < 0.001, 
one-way ANOVA) between patients with early, middle, and late phases of AD and healthy 
control subjects (Fig. 1). Post-hoc analysis (Tukey’s test) revealed that patients in early phase 
of AD had lower pDBH activity than patients in middle (p = 0.006) or late (p = 0.004) phase of 
AD, or than healthy control subjects (p = 0.0001).  
 
3.2. DBH gene polymorphisms and plasma DBH activity 
No significant deviation from the Hardy-Weinberg distribution was found in DBH (C-
970T) genotypes for patients with AD (χ
2 
= 0.620; df = 1; p = 0.431) and healthy control 
subjects (χ
2 
= 0.046; df = 1; p = 0.829). The distribution of the genotypes of DBH (C1603T) 
polymorphism did not deviate from the Hardy-Weinberg distribution in patients with AD (χ
2 
= 
0.533; df = 1; p = 0.465), while healthy subjects did (χ
2 
= 11.970; df = 1; p = 0.0005).  
There was no significant difference in the genotype or CC and T allele (CT+TT) 
carriers frequencies of the C-970T DBH and of C1603T DBH polymorphism between patients 
with AD and control subjects (Table 1). The 970T allele was found in 24.2% and 24.4% of 
patients with AD and healthy control subjects, respectively. The frequency of the 1603T allele 
was 5.6% in healthy controls and 4.8% in AD patients. 
In patients with AD pDBH activity differed significantly among the carriers of the CC 
(11.02 ± 5.9 nmol/min/ml), CT (6.71 ± 4.6 nmol/min/ml), and TT (3.20 ± 3.6 nmol/min/ml) 
genotypes of the DBH (C-970T) (F = 39.452; df = 2,204; p < 0.001).  A significant difference 
in pDBH was observed between healthy control subjects carriers of CC (20.16 ± 11.3 
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nmol/min/ml), CT (11.59 ± 7.8 nmol/min/ml), and TT (4.77 ± 1.7 nmol/min/ml) genotypes of 
the DBH (C-970T) (F =17.760; df = 2,87; p < 0.001).  This association was manifested in a co-
dominant manner. Regarding the other DBH polymorphism, there were no carriers of the TT 
genotype of the DBH (C1603T) in patients with AD, and therefore, groups were divided into 
CC and T allele (CT+TT) carriers. Plasma DBH activity did not differ significantly between 
the CC (9.27 ± 6.0 nmol/min/ml) and T allele (6.22 ± 3.4 nmol/min/ml) in patients with AD   
(F = 3.85; df = 1, 205, p = 0.051) and CC (16.51 ± 11.2 nmol/min/ml)  and T allele  (11.55 ± 
6.3 nmol/min/ml) healthy control subjects (F =1.48; df = 1,88; p < 0.227) carriers of the 
C1603T DBH. 
To explore the genetic influence on pDBH activity, further calculations evaluated the 
effects of DBH C-970T and C1603T polymorphism on pDBH activity. When pDBH activity 
was stratified according to the C-970T DBH genotype, two-way ANOVA revealed significant 
effects of both diagnosis (F = 25.721; df = 1; p < 0.001) and genotype (F = 48.772; df = 2; p < 
0.001) on pDBH activity, but no significant (F = 0.274; df = 2; p = 0.764) interaction between 
the diagnosis and genotype. The frequencies of the CC, CT and TT genotypes did not differ 
significantly (χ
2 
= 4.004; df = 4; p = 0.405) between patients in early (58.3%, 38.9%, 2.8%), 
middle (52.8%, 38.9%, 8.3%) and late (69.5%, 22.2%, 8.3%) stages of AD, respectively. 
Logistic regression showed no significant association (OR = 1.08; 95% CI 1.13-4.37; p = 
0.779) between AD and DBH CC homozygotes vs. T allele (CT+TT) carriers, controlled for 
age, gender, and ApoE4 allele. Two-way ANOVA on effect of C1603T polymorphism and 
diagnosis revealed significant effect of genotype (F = 4.298; df = 2; p <0.039), and diagnosis 
(F = 13.240; df = 1; p < 0.001) on pDBH, but the interaction between them was not statistically 
significant (F = 0.001; df = 2; p = 0.969). Logistic regression analysis adjusted for age, gender, 
and presence of ApoE4 allele was not significant (OR = 0.89; 95% CI 0.36-2.20; p = 0.814). 
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4. Discussion  
To our knowledge, this is the first study to compare both pDBH activity, DBH gene 
promoter variant (C-970T), and DBH exon 11 variant (C1603T) in patients with AD and age-
matched healthy controls. The most important findings of the present study are the occurrence 
of genotypes-independent decrease in pDBH activity in patients with AD compared to healthy 
controls, and the existence of a pronounced decrease in pDBH activity in the early stages of 
AD compared to values in later stages of AD and values in healthy controls. 
Our result of lower pDBH activity in AD compared to healthy subjects is in agreement 
with decreased plasma (Elrod et al., 1997) and CSF (Elrod et al., 1997; Raskind et al., 1999) 
NA levels in AD. Although the majority of pDBH protein originates from the peripheral 
noradrenergic neurons, a good correlation was found between plasma and CSF DBH activity 
(Lerner et al., 1978; O'Connor et al. 1994). In this respect, our result of altered pDBH activity 
in patients with AD may be in line with reduced DBH activity in the frontal and temporal 
cortex and hippocampus (Cross et al.,1981), decreased NA levels (Hoogendijk et al. 1999), and 
the loss of noradrenergic neurons (Lyness etal., 2003) in postmortem brains of patients with 
AD. Although there are no data in the literature, we can not exclude the possibility that the low 
pDBH activity in patients with AD is a consequence of degeneration of peripheral 
noradrenergic neurons in AD.  
There are several factors such as age, gender, medication, race, and genetic traits that 
might explain the differences in pDBH activity among patients with AD and healthy control 
subjects. Although aging is a well-known risk factor for the development of AD, no association 
was found between pDBH activity in healthy controls in the age up to 60 years (Paclt and 
Koudelova, 2004), in healthy controls (age range 60 to 90 years) and in patients with AD (age 
range 65 to 98 years) in the present study. 
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Gender is also one of the risk factors for the development of AD. The majority (89.4%) 
of our patients with AD were women, confirming the clinical observations of a higher AD 
prevalence in women than in men, probably due to the differences in life span between 
genders. In agreement with the results from previous studies in healthy controls (Ogihara et al., 
1975; Lerner et al., 1978; Arato et al., 1983), we have found that pDBH activity in both patients 
with AD and healthy subjects did not differ according to gender. Although some of our patients 
received psychotropic medication, the effect of medication on pDBH activity is likely 
negligible, as it has been reported that treatment with different neuroleptics (haloperidol, 
chlorpromazine, fluphenazine) in patients with schizophrenia (Baron et al., 1982), and with 
benzodiazepines and imipramine in patients with depression (Friedman et al., 1984) does not 
influence pDBH activity. A recent study showed ethnic differences in pDBH activity between 
African Americans and Americans of European descent (Tang et al., 2007; Chen et al., 2010) 
the African Americans having lower pDBH activity. However, the potential effect of ethnic 
differences on pDBH activity can be ignored, our study including only Caucasians of European 
(Croatian) origin.  
Because neuroinflammation could play an important role in the etiology of AD (Wenk 
et al., 2003; Heneka and O'Banion, 2007), a possible explanation for the differences in DBH 
activity between patients with AD and healthy controls may be that inflammatory mediators 
affect DBH activity (Mateo et al. 2006). Oxidative stress, as one of the consequences of 
neuroinflammation, produces neurotoxic agents such as reactive oxygen species and nitric 
oxide that inhibit DBH activity (Zhou et al., 2000). Apart from its role as neurotransmitter, NA 
can act as an anti-inflammatory and neuroprotective agent, regulating Aβ clearance and 
microglial Aβ phagocytosis (Heneka and O'Banion, 2007) by activation of neurotrophic 
pathways that protect against neuronal Aβ toxicity  (Counts and Mufson, 2010). Thus, low 
DBH activity may diminish the probable neuroprotective role of NA, and consequently make 
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individuals with lower DBH activity more susceptible to inflammation and development of 
AD. Alternatively, a decrease in DBH activity could reflect the neurodegenerative changes in 
the noradrenergic system, resulting in diminished NA concentration and altered dopamine/NA 
ratio, with a subsequent compensatory potential as a response to cholinergic deficit (Combarros 
et al., 2010). 
In line with our hypothesis that alterations in DBH activity are an index of the 
progression of AD, we found lower pDBH activity in the early stages of AD, and a gradual 
increase in enzyme activity with worsening of cognitive symptoms in the later stages of AD. 
Our results concur with the low and high NA CSF levels observed in patients with 
mild/moderate and severe AD, respectively (Elrod et al., 1997). A similar inverse correlation 
was observed between cognitive decline and DBH immunoreactivity in peripheral lymphocytes 
(Giubilei et al., 2004).  
Owing to the fact that DBH activity is under genetic control (Zabetian et al., 2001; 
Cubells and Zabetian, 2004), the possible effect of gene polymorphisms influencing the 
enzyme activity should be taken into account when searching for a potential difference in 
pDBH activity. Lower plasma DBH activity in our patients with AD than in healthy elderly 
subjects might be also induced by the individual differences in genetic traits.  In agreement 
with results obtained in ethnically diverse populations like African American (Tang et al., 
2005), Indian (Bhaduri and Mukhopadhyay, 2008), and German (Zabetian et al., 2001), our 
results confirm that the DBH C-970T polymorphism strongly influences plasma DBH activity 
in Caucasian (Croatian) subjects (Mustapic et al., 2007), with low and high pDBH activity in 
individuals homozygous for T and C allele of the C-970T DBH, respectively. The relationship 
between DBH activity and severity of AD in our study could be explained by genetic control of 
DBH activity. However, no significant differences in the distribution of the particular 
genotypes between groups of patients in early, middle, and late stage of AD were found. The 
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decline in early and increase of pDBH activity in the later stages of AD could not be attributed 
to different proportions of less (T allele) or more (C allele) effective enzyme variants. 
We have found a deviation from Hardy-Weinberg equilibrium for C1603T DBH 
polymorphisms in healthy controls.  The possible reason for the significant deviation could be 
the low frequency of the minor T allele in healthy subjects as suggested by Hosking et al. 
(Hosking et al. , 2004). 
Taking into account the genetic control of DBH activity by the C-970T DBH, we did 
not confirm our hypothesis that the decrease in plasma (present study) and postmortem brain 
(Cross et al.,1981) DBH activity in patients with AD is related to a higher frequency of the T 
allele. Our results do not support the suggestion that noradrenergic deficiency and homozygosis 
for the T allele of the C-970T DBH might increase the risk for the development of AD 
(Combarros et al., 2010; Mateo et al., 2006). The reasons for the discrepancies among studies 
may be related to the different number of patients with AD and healthy subjects, and 
differences in the geographical origin of subjects, namely Northern Europe and Northern Spain 
(Combarros et al., 2010) vs. Middle Europe (present study). However, it seems that relationship 
between T allele and AD depends on gender and age, because a significant association was 
found only in men younger than 75 years (Combarros et al., 2010). Therefore, the lack of 
association between the T allele and AD in our study and disagreement with the previous 
finding (Combarros et al., 2010) could be explained by higher prevalence of women and only 
10.6% of men, who were older than 75 years. 
Our results enhance the current knowledge of the role of DBH and NA in the etiology 
of AD (Weinshenker, 2008). Even though tyrosine hydroxylase is considered as a rate-limiting 
enzyme in catecholamine metabolism there is evidence that under certain conditions DBH can 
influence NA levels in brain and become rate-limiting (Cubells and Zabetian, 2004; Bourdelat-
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Parks et al., 2005; McMillan et al., 2011; Schroeder et al., 2010). These findings confirm the 
presumption that initial loss of noradrenergic neurons from the LC is compensated by the 
increased activity of the surviving neurons (American Psychiatric Association., 1994; 
Hoogendijk et al., 1999; Szot et al., 2006). Several compensatory mechanisms have been 
described (Szot, White, 2006; Weinshenker, 2008; Counts and Mufson, 2010: Fitzgerald, 2010), 
including stimulation of NA synthesis due to the increased expression of TH (Szot et al., 2006), 
decreased clearance of NA from the presynaptic terminals (Raskind et al., 1999), impaired NA 
turnover (Weinshenker, 2008; Counts and Mufson, 2010; Fitzgerald, 2010), and increased 
sprouting of the surviving noradrenergic neurons originating from LC (Szot et al., 2006). The 
determination of NA and its metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) revealed a 
high MHPG/NA ratio in frontal cortex and LC in AD (Hoogendijk et al., 1999), suggesting that 
increase in NA metabolism in remaining noradrenergic neurons could be also a potential 
compensatory mechanism for the loss of noradrenergic neurons. The increase in DBH activity 
and NA levels, calculated per neurons was also reported postmortem in AD cases compared to 
controls (Burke et al.,1999). Conversely, McMillan and collaborators recently observed an 
overall decrease in DBH mRNA in LC neurons of AD patients measured postmortem, but the 
amount of DBH mRNA expression/neuron in AD subjects was not significantly different from 
that in controls (McMillan et al., 2011). The lack of significant difference in mRNA DBH 
expression per neuron between AD subjects and controls (McMillan et al., 2011) is possibly 
revealing a compensatory effect as increased pDBH activity in a later stage, almost reaching 
the values of pDBH activity in healthy controls (Fig. 1) as opposed to low pDBH activity in 
early stage patients, who may have decreased DBH mRNA expression.  
A limitation of the present study is the sample size particularly of the control subjects. 
The number of healthy control subjects was limited due to exclusion criteria like the presence 
of somatic diseases that are often present in elderly subjects. Another limitation is the 
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measurement of peripheral pDBH activity at one time point, without individual longitudinal 
follow-up of pDBH activity during the progress of AD. In addition, cognitive decline in AD 
was determined using MMSE but not with other clinical scales, such as Clinical Dementia 
Rating Scores. The advantages of the study however are the determination of three biomarkers: 
pDBH activity and C-970T and C1603T DBH polymorphisms in patients with different stages 
of AD, the inclusion of the gender- and age-matched healthy controls, the power (0.8), and a 
sufficiently large sample size to determine the differences in pDBH activity.  
In conclusion, our results show genotypes-independent decrease in pDBH activity in 
patients with AD compared to enzyme activity in age-matched healthy controls. We did not 
confirm the association of low activity T allele variant of the DBH C-970T and AD. Despite 
the limitations of the study and the questionable significance of the alteration in peripheral 
pDBH activity and the central noradrenergic activity, the relationship between pDBH activity 
and severity of AD suggests that initial loss of noradrenergic neurons in the LC in AD could be 
compensated by increased activity and production of NA in surviving neurons. This finding 
indicates that in early phase of AD, treatment with drugs such as selective NA reuptake 
inhibitors is warranted for compensation of the loss of noradrenergic activity in LC. Further 
studies are necessary to confirm that altered DBH activity represents a compensatory 
mechanism for the loss of noradrenergic neurons in the early stages of AD. 
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Fig. 1. Plasma DBH activity in patients with different stages of AD (subdivided according to 
MMSE scores) and in healthy controls. Each column represents mean ± SD.  *p = 0.006 vs. 
middle stage; **p = 0.004 vs. late stage; *** p = 0.0001 vs. healthy controls (ANOVA; Tukey's 
test) 
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Table 1. Genotype and allele frequencies of the C-970T and 1603C/T DBH gene 
polymorphisms and plasma DBH activity, in patients with AD and elderly healthy controls 
stratified according to genotype. 
 
DBH polymorphism 
Healthy controls 
(90) 
AD patients 
(207) 
C-970T (rs1611115) 
Genotype N (%) N (%) 
CC 51 (57) 117 (56) 
CT 34 (38)   80 (39) 
TT 5 (5) 10 (5) 
 χ
2 
= 0.080; df = 2; p = 0.962 
CC homozygotes 51 (57) 117 (56) 
T allele carriers (CT+TT) 39 (43)   90 (44) 
 χ
2 
= 0.011; df = 1; p = 0.917 
C1603T (rs6271) 
Genotype N (%) N (%) 
CC 82 (91) 187 (90) 
CT 6 (7)   20 (10) 
TT 2 (2) 0 
 χ
2 
= 5.240; df = 2; p = 0.072 
CC homozygotes 82 (91) 187 (90) 
T allele carriers (CT+TT) 8 (9)   20 (10) 
 χ
2 
= 0.000; df = 1; p = 0.995 
N is the number of subjects 
 
